A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product (NCT05768269)
A Long-Term Follow-up Study for Subjects Previously Treated With A Century Therapeutics Cellular Therapy Product
🩺 Plain-English Summary (8th-Grade Level)
This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any long-term risks or late AEs that may be causally related to treatment with such cellular products.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- No Intervention (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- University of Southern California - Norris Comprehensive Cancer Center — Los Angeles, California
- University of Maryland Medical Center — Baltimore, Maryland
- Corewell Health — Grand Rapids, Michigan
- Levine Cancer Institute — Charlotte, North Carolina
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Swedish Cancer Institute — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (888) 506-7670
Email: trial_response_century@centurytx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematological Malignancy
- Halt Aging in Survivors of Blood Cancers — Omaha, Nebraska
- Membrane Target Detection for Leukemia Treatment — Columbia, Missouri
- Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia — Morgantown, West Virginia
- HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib — Detroit, Michigan
- Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances — Houston, Texas
Explore by condition: All Hematological Malignancy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.